Page 2 - Kiran Mazumdar Shaw

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Pharma sector can be of $200 bn by 2030 on innovative drugs: Biocon chief

Research-based incentives to develop innovative drugs can help the domestic pharmaceutical sector to be worth USD 200 billion by 2030, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Wednesday. Terming the pharmaceutical sector as a great contributor in the country's economic growth, she noted that the industry has even greater potential to grow in the years to come. "India's pharma industry size is estimated at about USD 65 billion today. And by 2030, it is expected to increase to USD 165 billion. Now, I believe it has a potential to even be greater and touch USD 200 billion by 2030," Mazumdar-Shaw told PTI. But such a level of growth cannot just be driven by generics and biosimilars, it has to involve drug innovation, she noted. "We have time to develop new drugs which could be blockbusters and I think what is required are research incentives to drive this kind of growth," Mazumdar-Shaw stated. The government has already come out with various research-linked incentive .

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biosimilars growth props up Biocon Q2 PAT by 168% to Rs 126 crore

On a sequential basis, the company exhibited a 1.15 per cent increase in revenue along with PAT, which rose 23.8 per cent

Serum Institute of India doubles Biocon investment to $300 million

The earlier investment by SILS in BBL was at a valuation of $4.9 billion, and the fresh $150-million investment pushes it up at $6 billion

Infosys announces Kiran Mazumdar-Shaw's retirement from company's board

D Sundaram appointed lead independent director of IT services company

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

I am devastated, will always be guided by John: Biocon chief Kiran Majumdar

Biocon Chief Kiran Majumdar-Shaw, who lost her husband, stated that she is devastated. Sharing her thoughts on social media, she maintained that she will always be guided by her husband John Shaw

Devastated to lose my husband: Biocon founder Kiran Mazumdar-Shaw

Biocon founder Kiran Mazumdar-Shaw said she was devastated to lose her husband and will miss him profoundly. John Shaw, who had served the Bengaluru-headquartered biopharmaceutical company as the Vice-Chairman and Non-Executive Director for over 22 years, passed away at a private hospital here on Monday. "I am devastated to lose my husband, my mentor and soul mate. I will always be spiritually guided by John as I pursue my purpose. Rest in Peace my darling John. Thank you for making my life so very special. I will miss you profoundly," Mazumdar-Shah said. John Shaw, a Scotsman and Indophile, headed a leading textiles MNC Madura Coats as Chairman and Managing Director before joining Biocon in 1999. "He has contributed majorly to the transformation of Biocon from a small enzymes company to a globally recognised biopharmaceutical company and has played an important role in ensuring the highest levels of corporate governance in the company, as well as, in the financial and strategic .

John Shaw, husband of Biocon chief Kiran Mazumdar Shaw, passes away

Biocon executive chairperson Kiran Mazumdar Shaw's husband John Shaw passed away on Monday morning in a private hospital, family sources said. He was 73. Shaw was admitted to the hospital where he was undergoing treatment, they said. The exact reason behind the death was not known. Shaw was the former vice chairman of the Bengaluru-headquartered Biocon Limited. He was an MA (Economics Honours) in History and Political Economy from the University of Glasgow in United Kingdom. He was also the former chairman of Madura Coats Limited and former finance and managing director of Coats Viyella Group.

Bengaluru encroachments: Penalise builders, BBMP, says Kiran Mazumdar-Shaw

Biotechnology industry veteran Kiran Mazumdar-Shaw has suggested penalising city civic body Bruhat Bengaluru Mahanagara Palike (BBMP) and Bangalore Development Authority (BDA) for giving permissions leading to encroachments of storm water drains (SWDs) that resulted in the recent floods. The Executive Chairperson of Bengaluru-headquartered biopharmaceuticals company Biocon said the anti-encroachment drive launched by the BMMP this week to clear illegal structures sitting on SWDs, is a long overdue measure to address water logging which caused unprecedented havoc in parts of Bengaluru two weeks ago. "The question that begs to be answered is whether there will be a parallel investigation into how the BBMP and BDA gave permissions in the first place", she told PTI. "Moreover, we need to go beyond knee jerk quick fixes and find holistic long term solutions. For example, razing buildings will impact helpless and innocent homeowners. Why not penalise developers and BDA/BBMP and use that

India at 75: Munjals to Mahindras - 20 visionary industrialists of India

In the decades since Independence, the enterprises steered by these business leaders have morphed into giants. Here's a look at 20 visionary industrialists of India

Biocon chief Kiran Majumdar-Shaw slams poor condition of Bengaluru roads

The arterial roads which are dug for various civic works are not being repaired. The potholes have resulted in several deaths in Bengaluru, triggering public outrage.

UK Rich List 2022: Hindujas on top, David and Simon Reuben in third spot

Sir James Dyson and his family are third on the list with wealth estimated at GBP 23 billion.

BJP hits out at Kiran Shaw for keeping mum on students carrying Bibles

The BJP used the signing of MoU for setting up the largest semiconductor fabrication unit in Karnataka to hit out at Shaw

BJP accuses Biocon chief of imposing personal, politically coloured opinion

The BJP accused her of imposing personal and 'politically coloured' opinion and conflating it with India's leadership in Information technology and biotechnology sectors

Glasgow University names research centre after Kiran Mazumdar-Shaw, John Shaw

The University of Glasgow has honoured John Shaw and Kiran Mazumdar-Shaw by naming its new research centre after them.

Biocon Executive Chairperson Kiran Mazumdar-Shaw elected as RSE fellow

Mazumdar-Shaw, who is also the Executive Chairperson of Biocon Biologics, will be joining RSE's current fellowship of around 1,700 fellows, the company said in a statement